- Home
- LTRN
LTRN
Lantern Pharma Inc.
as 06-06-2025 4:00pm EST
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 36.1M | IPO Year: | 2020 |
| Target Price: | $25.00 | AVG Volume (30 days): | 67.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.55 - $6.12 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Lantern Pharma Inc. (LTRN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | LTRN | 10% Owner | May 27 '25 | Sell | $2.98 | 56,237 | $168,418.85 | 125,332 | |
| Fletcher Aaron G.L. | LTRN | 10% Owner | May 27 '25 | Sell | $2.98 | 56,237 | $168,418.85 | 213,763 |
Latest Lantern Pharma Inc. News
LTRN Breaking Stock News: Dive into LTRN Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Insider Monkey
8 days ago
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models
Business Wire
9 days ago
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
Zacks Small Cap Research
19 days ago
LTRN: First Quarter 2025 Financial Results
Business Wire
23 days ago
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
Business Wire
a month ago
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
Benzinga
a month ago
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
Business Wire
a month ago
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
Compare LTRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LTRN Lantern Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.